Commercialized Products
Adult Chronic Immune Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Global Markets
Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- EMA Review
- Approved
Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Japan Phase 3
- Approved
Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- HC Review
- Approved
Clinical Trials**
Warm Antibody AIHA
Target: Spleen tyrosine kinase (SYK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Immune Disease
Target: Interleukin receptor associated kinases 1 and 4 (IRAK1/4)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Inflammatory Disease
Target: Receptor-interacting protein kinase (RIP1)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Oncology
Target: AXL receptor tyrosine kinase (AXL)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Dermatology
Target: Janus tyrosine kinase (JAK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Oncology
Target: Murine double minute 2 (MDM2)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
Chronic Asthma
Target: Janus tyrosine kinase (JAK)
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Approved
- Key:
- Company-sponsored Trials
- Partner-sponsored Trials
* Please see the TAVALISSE full Prescribing Information
** Investigational compounds in these indications have not been submitted for FDA review